EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Comparability of input parameters in the German Retina.net ROP registry and the EU‐ROP registry – An exemplary comparison between 2011 and 2021

K Winter, J M Pfeil iD, H Engmann, S Aisenbrey, B Lorenz, K Hufendiek, H Breuss, M Khattab, D Süsskind, V Kakkassery, W A Lagrèze iD, T Barth und 10 weitere

Acta Ophthalmologica · 2024

DOI: 10.1111/aos.15753 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Ophthalmologica, 2024. Verfasst von K Winter und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany. Hauptthemen laut MEDLINE: Ranibizumab, Retinopathy of Prematurity. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer, Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The German Retina.net ROP registry and its Europe‐wide successor, the EU‐ROP registry, collect data from patients treated for ROP. This analysis compares input parameters of these two registries to establish a procedure for joint analyses of different registry data using exemplary datasets from the two registries.

Methods

Exemplary datasets from the two databases over a 1‐year period each (German Retina.net ROP Registry, 2011, 22 infants; EU‐ROP Registry, 2021, 44 infants) were compared. The parameters documented in the two databases were aligned and analysed regarding demographic parameters, treatment modalities, complications within first 24 h and retreatments.

Results

The current analysis showed that data can be aligned for joint analyses with some adjustments within the data structure. The registry with more detailed data collection (EU‐ROP) needs to be reduced regarding granularity in order to align the different registries, as the registry with lower granularity determines the level of analyses that can be performed in a comparative approach. In the exemplary datasets, we observed that the overall most common ROP severity in both registries was zone II, 3+ (2011: 70.5%; 2021: 65%), with decreasing numbers of clock hours showing preretinal neovascularisations (2011: 10–12 clock hours in 29% of cases, 2021: 4–6 clock hours in 38%). The most prevalent treatment method was laser coagulation in 2011 (75%) and anti‐VEGF therapy in 2021 (86.1%). Within the anti‐VEGF group, all patients were treated with bevacizumab in 2011 and with ranibizumab in 2021. Retreatment rates were comparable in 2011 and 2021.

Conclusion

Data from two different ROP registries can be aligned and jointly analysed. The analysis reveals a paradigm shift in treatment modalities, from predominantly laser to anti‐VEGF, and within the anti‐VEGF group from bevacizumab to ranibizumab in Germany. In addition, there was a trend towards earlier treatment in 2021.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RanibizumabRetinopathy of PrematurityInfant, NewbornInfantHumansBevacizumabAngiogenesis InhibitorsVascular Endothelial Growth Factor AIntravitreal InjectionsRetinaLaser CoagulationRegistriesGestational Age

Stichwörter der Autor:innen

ROPanti‐VEGFlaser coagulationobservational studyregistryretinopathy of prematurity

Substanzen

BevacizumabRanibizumabAngiogenesis InhibitorsVascular Endothelial Growth Factor A

Autor:innen und Institutionen

  • Department of Ophthalmology, University Medicine Greifswald, Greifswald, Germany.
  • Department of Ophthalmology, Vivantes Klinikum Neukoelln, Berlin, Germany.
  • Department of Ophthalmology, University Medicine Giessen and Marburg GmbH Giessen Campus, Giessen, Germany.
  • University Eye Hospital, Hannover Medical School, Hannover, Germany.
  • Department of Ophthalmology, HELIOS Klinikum Berlin-Buch, Berlin, Germany.
  • Department of Ophthalmology, University Medical Center Goettingen, Goettingen, Germany.

ORCID-Profile: J M Pfeil, W A Lagrèze, R Liegl, T U Krohne, A Stahl

Förderung

  • Bayer
  • Novartis

Zitieren

APA

Winter, K., Pfeil, J. M., Engmann, H., Aisenbrey, S., Lorenz, B., Hufendiek, K., Breuss, H., Khattab, M., Süsskind, D., Kakkassery, V., Lagrèze, W. A., Barth, T., Liegl, R., Bründer, M. C., Skevas, C., Goldammer, I., Glitz, B., Michalewicz, E., Krohne, T. U., …, & Retina.net ROP and EU‐ROP registry study groups (2024). Comparability of input parameters in the German Retina.net ROP registry and the EU‐ROP registry – An exemplary comparison between 2011 and 2021. Acta Ophthalmologica. https://doi.org/10.1111/aos.15753

Vancouver

Winter K, Pfeil JM, Engmann H, Aisenbrey S, Lorenz B, Hufendiek K, et al. Comparability of input parameters in the German Retina.net ROP registry and the EU‐ROP registry – An exemplary comparison between 2011 and 2021. Acta Ophthalmologica. 2024. doi:10.1111/aos.15753

BibTeX
@article{Winter2024,
  author = {Winter, K and Pfeil, J M and Engmann, H and Aisenbrey, S and Lorenz, B and Hufendiek, K and Breuss, H and Khattab, M and Süsskind, D and Kakkassery, V and Lagrèze, W A and Barth, T and Liegl, R and Bründer, M C and Skevas, C and Goldammer, I and Glitz, B and Michalewicz, E and Krohne, T U and Bartmann, I R and Stahl, A and Retina.net ROP and EU‐ROP registry study groups, Retina.net ROP and EU‐ROP registry study groups},
  title = {Comparability of input parameters in the German Retina.net ROP registry and the EU‐ROP registry – An exemplary comparison between 2011 and 2021},
  journal = {Acta Ophthalmologica},
  year = {2024},
  doi = {10.1111/aos.15753}
}
Kostenlos starten →